Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetratricopeptide repeat domain 8 (TTC8), also known as BBS8, encodes a protein that is a component of the BBSome complex, essential for the formation and maintenance of primary cilia in eukaryotic cells[1][3][6]. TTC8 localizes to ciliary structures, including the basal body and the connecting cilium of photoreceptors, and is involved in sorting specific membrane proteins to primary cilia[1][6]. Mutations in TTC8 are directly linked to Bardet-Biedl syndrome, a ciliopathy characterized by a range of symptoms, most notably retinal dystrophy and, in some cases, have been implicated in non-syndromic retinitis pigmentosa[1][4][5]. While TTC8 is not currently established as a direct therapeutic target (i.e., not a receptor, enzyme, or transporter with known drug interactions), its role in ciliary biology marks it as significant in the pathology of ciliopathies[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetratricopeptide repeat domain 8 (TTC8).